Cash Flow Statement

Amortization Amortization Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Ratios

Quantum Biopharma (QNTM) Capital Expenditures (2022)

Quantum Biopharma's Capital Expenditures history spans 1 years, with the latest figure at $230839.0 for Q4 2022.

On a quarterly basis, Capital Expenditures changed N/A to $230839.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $113958.0, a N/A change, with the full-year FY2022 number at $113958.0, changed N/A from a year prior.
Capital Expenditures hit $230839.0 in Q4 2022 for Quantum Biopharma, up from -$96917.0 in the prior quarter.
Over the last five years, Capital Expenditures for QNTM hit a ceiling of $230839.0 in Q4 2022 and a floor of -$96917.0 in Q3 2022.